Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Frydenberg

Showing results (91-100 of 182) with videos related to

Pageof 19
Sort By:
European Urology Oncology|August 24, 2024
Cost-utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual CareDaniel Lindsay, Penelope Schofield, Matthew J Roberts, et al.
BJUI Compass|January 5, 2024
Co-designing an online treatment decision aid for men with low-risk prostate cancer: NavigatePenelope Schofield, Amelia Hyatt, Alan White, et al.
BJU International|May 16, 2023
Can <sup>68</sup> Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?Yash Khanna, Vidyasagar Chinni, Kavitha Gnanasambantham, et al.
The Journal of Pathology|July 22, 2014
A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitmentStuart J Ellem, Renea A Taylor, Luc Furic, et al.
The Journal of Urology|September 21, 2021
<sup>68</sup>Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate CancerAlan L Xue, Arveen A Kalapara, Zita E Ballok, et al.
European Urology|December 20, 2020
Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA TrialRafael E de Feria Cardet, Michael S Hofman, Tatiana Segard, et al.
The Medical Journal of Australia|October 2, 2022
Modern paradigms for prostate cancer detection and managementIsabella Sc Williams, Aoife McVey, Sachin Perera, et al.
Pathology|September 1, 2012
Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancerJohn Mills, Alice Oliver, Justin C Sherwin, et al.
JAMA Network Open|January 17, 2025
Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active SurveillanceIvo I de Vos, Daan Nieboer, Mark Frydenberg, et al.
Plos One|April 20, 2018
Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancerDouglas H Campbell, Maria E Lund, Aline L Nocon, et al.
Pageof 19

Showing results (91-100 of 182) with videos related to

Sort By:
Pageof 19
European Urology Oncology|August 24, 2024
Cost-utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual CareDaniel Lindsay, Penelope Schofield, Matthew J Roberts, et al.
BJUI Compass|January 5, 2024
Co-designing an online treatment decision aid for men with low-risk prostate cancer: NavigatePenelope Schofield, Amelia Hyatt, Alan White, et al.
BJU International|May 16, 2023
Can <sup>68</sup> Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?Yash Khanna, Vidyasagar Chinni, Kavitha Gnanasambantham, et al.
The Journal of Pathology|July 22, 2014
A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitmentStuart J Ellem, Renea A Taylor, Luc Furic, et al.
The Journal of Urology|September 21, 2021
<sup>68</sup>Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate CancerAlan L Xue, Arveen A Kalapara, Zita E Ballok, et al.
European Urology|December 20, 2020
Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA TrialRafael E de Feria Cardet, Michael S Hofman, Tatiana Segard, et al.
The Medical Journal of Australia|October 2, 2022
Modern paradigms for prostate cancer detection and managementIsabella Sc Williams, Aoife McVey, Sachin Perera, et al.
Pathology|September 1, 2012
Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancerJohn Mills, Alice Oliver, Justin C Sherwin, et al.
JAMA Network Open|January 17, 2025
Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active SurveillanceIvo I de Vos, Daan Nieboer, Mark Frydenberg, et al.
Plos One|April 20, 2018
Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancerDouglas H Campbell, Maria E Lund, Aline L Nocon, et al.
Pageof 19